Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms

CNS Drugs

Volumn 23, Issue SUPPL. 1, 2009, Pages 9-20

  Spencer, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; CLONIDINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LITHIUM; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; PLACEBO; PSYCHOSTIMULANT AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VALPROIC ACID;

ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONDUCT DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSLEXIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; KLEPTOMANIA; LEARNING DISORDER; MAJOR DEPRESSION; MATURATION; MENTAL DISEASE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; ONSET AGE; OPPOSITIONAL DEFIANT DISORDER; POLYPHARMACY; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPATHY; PSYCHOSOCIAL CARE; REVIEW; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; SPEECH THERAPY; SUBSTANCE ABUSE; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CHILD BEHAVIOR DISORDERS; COGNITION DISORDERS; COMORBIDITY; CONDUCT DISORDER; HUMANS; MOOD DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 67849093832     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200923000-00003     Document Type: Review

References (100)

1. Centers for Disease Control. Mental health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/ hyperactivity disorder - United States, 2003. Morbidity and Mortality Weekly Report 2005; 2: 842-7
2. Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007; 161: 857-64
3. Rowland AS, Umbach DM, Stallone L, et al. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health 2002; 92: 231-4
4. Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002; 111: 279-89
5. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157: 816-8
6. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord 2005; 9: 384-91
7. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-23
8. Busch B, Biederman J, Cohen LG, et al. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatry Serv 2002; 53: 1103-11
9. Costello EJ, Mustillo S, Erkanli A, et al. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 2003; 60: 837-44
10. Lomas B, Gartside P. ADHD in adult psychiatric out-patients. Psychiatry Serv 1999; 50: 705
11. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Compr Psychiatry 1996; 37: 393-401
12. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996; 53: 437-46
13. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 1996; 35: 1193-204
14. Biederman J, Faraone S, Milberger S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1996; 35: 343-51
15. Biederman J, Petty CR, Dolan C, et al. The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med 2008; 1-10
16. Nierenberg AA, Miyahara S, Spencer T, et al. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry 2005; 57: 1467-73
17. Biederman J, Petty CR, Wilens TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008; 165: 107-15
18. Christiansen H, Chen W, Oades RD, et al. Co-transmission of conduct problems with attention-deficit/hyperactivity disorder: familial evidence for a distinct disorder. J Neural Transm 2008; 115:163-75
19. Grizenko N, Kovacina B, Ben Amor L, et al. Relationship between response in methylphenidate treatment in children with ADHD and psychopathy in their families. J Am Acad Child Adolesc Psychiatry 2006; 45: 47-53
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). 4 ed. Washington (DC): American Psychiatric Association; 2000
21. MTA Study Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088-96
22. Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 240-8
23. Harpold T, Biederman J, Gignac M, et al. Is oppositional defiant disorder a meaningful diagnosis in adults? Results from a large sample of adults with ADHD. J Nerv Ment Dis 2007; 195: 601-5
24. Loeber R, Burke JD, Lahey BB. What are adolescent antecedents to antisocial personality disorder? Crim Behav Ment Health 2002; 12: 24-36
25. Marshal MP, Molina BS. Antisocial behaviors moderate the deviant peer pathway to substance use in children with ADHD. J Clin Child Adolesc Psychol 2006; 35: 216-26
26. Wilens TE, Kwon A, Tanguay S, et al. Characteristics of adults with attention deficit hyperactivity disorder plus substance use disorder: the role of psychiatric comorbidity. Am J Addict 2005; 14: 319-27
27. Semiz UB, Basoglu C, Oner O, et al. Effects of diagnostic comorbidity and dimensional symptoms of attention-deficit-hyperactivity disorder in men with antisocial personality disorder. Aust N Z J Psychiatry 2008; 42: 405-13
28. CPP Research Group. Fast track randomized controlled trial to prevent externalizing psychiatric disorders: findings from grades 3 to 9. J Am Acad Child Adolesc Psychiatry 2007; 46: 1250-62
29. Steiner H, Remsing L. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 126-41
30. van Lier PA, Vuijk P, Crijnen AA. Understanding mechanisms of change in the development of antisocial behavior: the impact of a universal intervention. J Abnorm Child Psychol 2005; 33: 521-35
31. Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry 2007; 68: 422-7
32. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 2002; 41: 253-61
33. Sinzig J, Dopfner M, Lehmkuhl G, et al. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 2007; 17: 421-32
34. Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 266-79
35. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008; 121: e314-20
36. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54: 1073-80
37. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004; 14: 243-54
38. Kawley G. Risperidone in comorbid ADHD and ODD/CD. J Am Acad Child Adolesc Psychiatry 1999; 38: 1327-8
39. Janssen. Risperdal PI. 2008. (Data on file)
40. Otsuka Pharmaceutical Company, Ltd. Abilify (aripiprazole). Prescribing information. Tokyo, Japan, 2008
41. Biederman J, Wilens TE, Mick E, et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998; 44: 269-73
42. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psycho-stimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005; 15: 764-76
43. Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. J Addict Dis 2004; 23: 31-40
44. Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652-8
45. Biederman J, Monuteaux MC, Mick E, et al. Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder. Biol Psychiatry 2006; 59: 258-64
46. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993; 34: 75-82
47. Levin FR, Bisaga A, Raby W, et al. Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. J Subst Abuse Treat 2008; 34: 80-9
48. Lambert NM, Hartsough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 1998; 31: 533-44
49. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179-85
50. Amiri S, Mohammadi MR, Mohammadi M, et al. Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 145-9
51. Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008; 152: 394-9
52. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10: 311-20
53. Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 180-8
54. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002; 159: 36-42
55. Biederman J, Faraone S, Mick E, et al. Child Behavior Checklist findings further support comorbidity between ADHD and major depression in a referred sample. J Am Acad Child Adolesc Psychiatry 1996; 35: 734-42
56. Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996; 62: 213-9
57. Biederman J, Mick E, Faraone SV. Depression in attention deficit hyperactivity disorder (ADHD) children: "true" depression or demoralization? J Affect Disord 1998; 47: 113-22
58. Eli Lilly and Company. Prozac (fluoxetine capsules). Prescribing information. Indianapolis, Indiana, 2007
59. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003; 290: 1033-41
60. Wagner KD, Robb AS, Findling RL, et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004; 161: 1079-83
61. Gadow KD, Nolan EE, Sverd J, et al. Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder. J Clin Psychopharmacol 2002; 22: 267-74
62. Candy M, Jones L, Williams R, et al. Psychostimulants for depression. Cochrane Database Syst Rev 2008; 2: CD006722
63. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683-96
64. Forest Pharmaceuticals I. Lexapro PI. 2008. (Data on file)
65. Pfizer Inc. Zoloft (sertraline hydrochloride). Prescribing information. New York, New York, 2007
66. Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007; 17: 407-20
67. Findling RL. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 1996; 6: 165-75
68. ALZA Corp. Concerta PI. 2007. (Data on file)
69. Shire Pharmaceuticals. Adderall XR. PI. 2007. (Data on file)
70. Luty SE, Carter JD, McKenzie JM, et al. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 2007; 190: 496-502
71. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007; 64: 1132-43
72. Riggs PD, Mikulich-Gilbertson SK, Davies RD, et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med 2007; 161: 1026-34
73. Youngstrom EA, Birmaher B, Findling RL. Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis. Bipolar Disord 2008; 10: 194-214
74. Masi G, Perugi G, Toni C, et al. Attention-deficit hyper-activity disorder - bipolar comorbidity in children and adolescents. Bipolar Disord 2006; 8: 373-81
75. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 107-25
76. Noven Therapeutics, LLC. Lithobid (lithium carbonate). Prescribing information. Miami, Florida, 2008
77. Pavuluri MN, Henry DB, Carbray JA, et al. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol 2006; 16: 336-50
78. Tramontina S, Zeni CP, Pheula GF, et al. Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial. CNS Spectr 2007; 12: 758-62
79. Scheffer RE, Kowatch RA, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162: 58-64
80. Soutullo CA, Casuto LS, Keck Jr PE. Gabapentin in the treatment of adolescent mania: a case report. J Child Adolesc Psychopharmacol 1998; 8: 81-5
81. Wilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003; 54: 9-16
82. Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1445-53
83. Galanter CA, Carlson GA, Jensen PS, et al. Response to methylphenidate in children with attention deficit hyper-activity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyper-activity disorder titration trial. J Child Adolesc Psychopharmacol 2003; 13: 123-36
84. Consoli A, Bouzamondo A, Guile JM, et al. Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis. Can J Psychiatry 2007; 52: 323-8
85. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40: 147-58
86. Biederman J, Faraone S, Mick E, et al. Attention-deficit hyperactivity disorder and juvenile mania: an overlooked comorbidity? J Am Acad Child Adolesc Psychiatry 1996; 35: 997-1008
87. GlaxoSmithKline. Paxil PI. 2008. (Data on file)
88. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 2005; 44: 418-27
89. March JS, Swanson JM, Arnold LE, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol 2000; 28: 527-41
90. van der Oord S, Prins PJ, Oosterlaan J, et al. Treatment of attention deficit hyperactivity disorder in children: predictors of treatment outcome. Eur Child Adolesc Psychiatry 2008; 17: 73-81
91. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989; 28: 882-7
92. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001; 22: 60-73
93. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1119-27
94. Kratochvil C. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005; 9: 915-24
95. Morrow BA, George TP, Roth RH. Noradrenergic alpha-2 agonists have anxiolytic-like actions on stress-related behavior and mesoprefrontal dopamine biochemistry. Brain Res 2004; 1027: 173-8
96. Willcutt EG, Pennington BF, Olson RK, et al. Understanding comorbidity: a twin study of reading disability and attention-deficit/hyperactivity disorder. Am J Med Genet Part B (Neuropsychiatr Genet) 2007; 144B: 709-14
97. Shanahan MA, Pennington BF, Yerys BE, et al. Processing speed deficits in attention deficit/hyperactivity disorder and reading disability. J Abnorm Child Psychol 2006; 34: 585-602
98. Daniel SS, Walsh AK, Goldston DB, et al. Suicidality, school dropout, and reading problems among adolescents. J Learn Disabil 2006; 39: 507-14
99. Rasmussen K, Almvik R, Levander S. Attention deficit hyperactivity disorder, reading disability, and personality disorders in a prison population. J Am Acad Psychiatry Law 2001; 29: 186-93
100. Gaab N, Gabrielei JDE, Deutsch GK, et al. Neural correlates of rapid auditory processing are disrupted in children with developmental dyslexia and ameliorated with training: an fMRI study. Restorat Neurol Neurosci 2007; 25: 295-310